Research

Hormonal

Use of GLP-1 receptor agonists (GLP-1 RAs) significantly reduces the risk of developing lymphedema in patients undergoing axillary lymph node dissection (ALND) for breast cancer, independent of diabetes status.

If you are having breast cancer surgery that involves removing lymph nodes, ask your doctor if GLP-1 RAs (like semaglutide or liraglutide) might help reduce your risk of lymphedema, especially if you have a higher BMI or insulin resistance. The study suggests these drugs may significantly lower the risk, but more research is needed to confirm this.

ModerateSupportsMEDIUM confidence
On multivariate regression analysis, patients who were treated with GLP-1 RA were 86% less likely to develop lymphedema compared to the non-GLP-1 RA cohort (OR 0.14, 95% CI 0.04–0.32, p < 0.0001).
Stav Brown et al. · Frontiers in Pharmacology · 2024

Why this rating

The study is retrospective and observational, relying on diagnosis codes rather than objective metrics, which introduces potential bias and limits causal inference.

Source

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)

Stav Brown et al. · Frontiers in Pharmacology · 2024

DOI 10.3389/fphar.2024.1457363

cohort · n=3830Cited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →